Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin A1c levels. For more information about this Pilot Study, call Pico-Tesla at 303-795-3222.

In an Open-Label Study that was the stimulus for the Pilot Study, 10 patients with type 2 diabetes were given three treatments per week with Magneceutical™ therapy for a total of 13 weeks. Seven (7) of these patients were taking prescription oral medications to manage their type 2 diabetes, and three patients were not. The mean A1c levels of the seven patients who were taking prescription oral medications while receiving Magneceutical™ therapy were reduced by a “clinically significant” amount at the end of the 13-week study, while the mean A1c levels of the three patients who were not on drug therapy were not reduced.

The protocols for the Open-Label Study and the current Pilot Study were developed in consultation with Michael McDermott, M.D., Director, Endocrinology and Diabetes Practice, University of Colorado Hospital, Aurora, Colo.; and with Mitchell Gershten, M.D., an internist and staff physician at Saint Mary’s Hospital in Grand Junction, Colo.

“The subjects of the Pilot Study are being treated with our Resonator system three times a week for 13 weeks at approximately 90 minutes per treatment,” said Allen Braswell, president and CEO of Pico-Tesla. “The primary outcome of this Pilot Study will be measurement of improvement in the subjects’ hemoglobin A1c level after 13 weeks of treatment compared to baseline. For people without diabetes, the normal range for the hemoglobin A1c test is between 4% and 6%. The higher the hemoglobin A1c, the higher the risks of developing complications related to diabetes,” said Braswell.

Allen Braswell will be presenting the Pico-Tesla story to investors at next month’s “OneMedForum 2010” finance conference in San Francisco, Jan. 12-14, at the Sir Francis Drake Hotel.

Diabetes mellitus type 2 or type 2 diabetes (formerly called adult-onset diabetes), a disorder characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency, is often initially managed by increasing exercise and dietary modification; prescription medications are typically needed as the disease progresses. There are nearly 24 million people in the U.S. (almost 8% of the population) with diabetes, with about 18 million being diagnosed—90% of whom are Type 2. With prevalence rates doubling between 1990 and 2005, CDC has characterized the increase as an epidemic.

Magneceutical™ Therapy involves the use of an extremely low-level electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—intended to improve a number of the signs and symptoms of Parkinson’s and other diseases, including Type 2 Diabetes.

An animal study—published in the April 1, 2008, issue of BioMagnetic Research and Technology—concluded: “The evidence suggests that long term exposure to electromagnetic fields with a well-defined frequency may have relevant effects on parameters such as body weight, blood glucose and fatty acid metabolism.”